Business · 17/08/2006Updated: 10/17/2026 · 1 min read
FDA's Psychopharmacologic Drugs Advisory Committee to Review Amendment of Psychopharmacologic Drugs Notice
The Psychopharmacologic Drugs Advisory Committee will review the FDA's amendment to the Psychopharmacologic Drugs Notice, a regulatory document that outlines the agency's approach to reviewing new psychopharmacologic drugs
Original source language: Federal Register — Food and Drug AdministrationOpen original release →